MOTS-c analogExperimental Peptides
Mots-c analog (CB4211)
A clinical-stage MOTS-c analog from CohBar Inc. being developed for NASH and obesity. Designed to replicate the metabolic benefits of endogenous MOTS-c with improved drug-like properties.
NASH-treatmentmetabolic-improvementmitochondrial-peptideexperimental
3D Structure
3D Structure
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
No mass spec data
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
A clinical-stage MOTS-c analog from CohBar Inc. being developed for NASH and obesity. Designed to replicate the metabolic benefits of endogenous MOTS-c with improved drug-like properties.